Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  panobinostat
Find trials that include:  Any drugs shown
Results 1-14 of 14 for your search:
Start Over
Panobinostat and Pemetrexed Disodium in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 08-036, NCI-2011-02483, NCT00907179
Panobinostat and Combination Chemotherapy in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2010-0065, NCI-2012-01779, NCI-2010-01770, NCT01169636
Panobinostat and Everolimus in Treating Patients with Metastatic or Unresectable Renal Cell Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 146308, NCI-2009-01599, NCT01037257, NCT01582009
Everolimus and Panobinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: Pro00012947, NCI-2013-02164, NCT00978432
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC0986, NCI-2010-02326, 10-004705, CLBH589BUS59T, NCT01261247
Panobinostat in Treating Patients with Recurrent or Refractory Hodgkin or Non-Hodgkin Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 147408, NCI-2009-01605, NCT01032148
Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM)
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2010-0733, NCI-2011-00316, NCT01301807
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 8 to 21
Trial IDs: T2009-012, NCI-2012-00054, NCT01321346
Panobinostat and Carfilzomib in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: WCI2011-11MMRC036, NCI-2012-00161, 49368, IRB00049368, MMRC: 036, NCT01549431
Panobinostat, Lenalidomide, Bortezomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13-262, NCI-2013-02008, CLBH589BUS82T, NCT01965353
Panobinostat and Ipilimumab in Treating Patients With Stage III or IV Melanoma That Cannot Be Removed By Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC 17439, NCI-2014-00176, NCT02032810
Ixazomib, Panobinostat, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE 4A13, NCI-2014-00228, CLBH589DUS92T, NCI-2014-00267, US92T, NCT02057640
Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: CLBH589DUS94X, NCI-2014-02268, NCT02204553
Start Over